EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Digital speech‐based markers to advance prognosis in Alzheimer's disease

Melissa Lee, Stephan Meylan, Eli Shobin, SpeechDx Consortium, Laura Nisenbaum, Aishwarya Sukumar, Lampros Kourtis

Alzheimer's & Dementia · 2026-06 · 22 (6)

DOI: 10.1002/alz.71489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 19.06.2026. Verfasst von Melissa Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Drug Discovery Foundation, New York, New York, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Speech. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator, Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government, Health Department of the Catalan Government, Ajuntament de Barcelona, Spanish Ministry of Science and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Validated prognostic tools are essential to advance drug development and clinical care in Alzheimer's disease, particularly as the field shifts toward the prevention of cognitive decline. While progress has been made in developing blood‐based biomarkers for the early detection of amyloid pathology, amyloid positivity alone does not reliably predict progression to symptomatic disease. Digital markers can serve as complementary prognostic tools to inform early intervention strategies. Among digital markers, speech‐based markers offer a scalable, non‐invasive, and cost‐effective approach to predicting and monitoring cognitive decline. However, the development of validated speech‐based tools has been constrained by the lack of large, multilingual datasets with longitudinal sampling, deep phenotyping, harmonized clinical and biomarker data, and adequate representation of preclinical populations. SpeechDx is a 3‐year, multinational, multilingual observational study ( n = 2006) designed to address these gaps and accelerate the development of speech‐based tools to inform early risk assessment, enable timely intervention, and guide personalized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersSpeechHumansPrognosisDisease ProgressionDigital Health

Stichwörter der Autor:innen

Alzheimer's diseaseartificial intelligencebiomarkersblood biomarkerscognitioncognitive impairmentcognitive markersdementiadiagnosisdigital markersdisease monitoringprognosisprognostic biomarkersspeech

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Alzheimer's Drug Discovery Foundation, New York, New York, USA.
  • Department of Linguistics, University of California, Berkeley, Berkeley, California, USA.
  • Gates Ventures, Kirkland, Washington, USA.

Förderung

  • Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator
  • Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government
  • Health Department of the Catalan Government, Ajuntament de Barcelona, Spanish Ministry of Science and Innovation
  • American Heart Association
  • NIH/NIA
  • Alzheimer's Association
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Lee, M., Meylan, S., Shobin, E., SpeechDx Consortium, Nisenbaum, L., Sukumar, A., & Kourtis, L. (2026). Digital speech‐based markers to advance prognosis in Alzheimer's disease. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71489

Vancouver

Lee M, Meylan S, Shobin E, SpeechDx Consortium, Nisenbaum L, Sukumar A, et al. Digital speech‐based markers to advance prognosis in Alzheimer's disease. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71489

BibTeX
@article{Lee2026,
  author = {Lee, Melissa and Meylan, Stephan and Shobin, Eli and SpeechDx Consortium, SpeechDx Consortium and Nisenbaum, Laura and Sukumar, Aishwarya and Kourtis, Lampros},
  title = {Digital speech‐based markers to advance prognosis in Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {6},
  doi = {10.1002/alz.71489}
}
Kostenlos starten →